Pragmatic Trial Of Alerts for Use of Mineralocorticoid Receptor Antagonists (PROMPT-MRA)
Diseases of the Cardiovascular System
What is the purpose of this trial?
The primary objective of this study is to determine if a best practice alert (BPA) system that prompts providers to consider the addition of a mineralocorticoid receptor antagonist (MRA) in eligible patients with heart failure with reduced ejection fraction (HFrEF) will result in increased prescription of this guideline-recommended therapy. The system will also inform providers about FDA-approved potassium binders for the treatment of hyperkalemia if elevated potassium is a barrier for MRA use and will provide educational information on the evidence for MRA therapy in these patients.
- Ages18 years and older
- Trial withRelypsa, Inc.
- Start Date09/22/2021
- End Date12/01/2023
- Last Updated01/16/2022
- Study HIC#2000030513